Adverse outcome analyses of observational data: Assessing cardiovascular risk in HIV disease

Clinical Infectious Diseases

Volumn 54, Issue 3, 2012, Pages 408-413

  Triant, V A ^a   Josephson, F ^b   Rochester, C G ^c   Althoff, K N ^d   Marcus, K ^c   Munk, R ^e   Cooper, C ^c   D'Agostino, R B ^f   Costagliola, D ^g,h,i   Sabin, C A ^j   Williams, P L ^k   Hughes, S ^l   Post, W S ^m   Chandra Strobos, N ⁿ   Guaraldi, G ^o   Young, S S ^p   Obenchain, R ^q   Bedimo, R ^r   Miller, V ^s   Strobos, J ^s  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f Boston University   (United States)

^g SORBONNE UNIVERSITÉ   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l GLAXOSMITHKLINE   (United Kingdom)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^o UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^p NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^q Risk Benefit Statistics LLC   (United States)

^r UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^s UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFOUNDING VARIABLE; EPIDEMIOLOGICAL DATA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION RISK; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; DATA INTERPRETATION, STATISTICAL; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RESEARCH DESIGN; RISK FACTORS;

EID: 84855884597     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir829     Document Type: Review

References (43)

1. US Department of Health and Human Services: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2011:1-166.
2. D'Agostino RB, Kwan H. Measuring effectiveness. What to expect without a randomized control group. Med Care 1995;33:AS95-105.
3. 21 U. S. C. § 355 (k).
4. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group. Stat Med 1999;18:1905-42.
5. ICH Harmonised Tripartite Guideline. Pharmacovigilance planning-sections 3.2.1/Annex 4. In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2004.
6. US Food and Drug Administration. The sentinel initiative: National strategy for monitoring medical product safety. 2008.
7. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9. (Pubitemid 351289042)
8. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-94.
9. Lau B, Gange SJ, Moore RD. Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses 2007;23:769-76. (Pubitemid 47047915)
10. McComsey GA, O'Riordan M, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007;21:921-7. (Pubitemid 46684323)
11. Miller TL, Orav EJ, Lipshultz SE, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 2008;153:491-7.
12. Shah AS, Dolan LM, Gao Z, Kimball TR, Urbina EM. Clustering of risk factors: a simple method of detecting cardiovascular disease in youth. Pediatrics 2011;127:e312-8.
13. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33:506-12. (Pubitemid 36886080)
14. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-7.
15. Lang S, Mary-Krause M, Cotte L, et al. Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS 2010;24:1228-30.
16. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92:2506-12. (Pubitemid 47037350)
17. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008;118:198-210.
18. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35. (Pubitemid 46658704)
19. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010;170:1228-38.
20. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-86. (Pubitemid 38393320)
21. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-30.
22. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26.
23. Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011;53:84-91.
24. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009;51:20-8.
25. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011;25:1289-98.
26. Cruciani M, Zanichelli V, Serpelloni G, et al. ABACAVIR use and cardiovascular disease events: a meta-analysis of published and unpublished data. AIDS 2011;25:1993-2004.
27. Ding X, Andraca-Carrera E, Cooper C, et al. No association of myocardial infarction with abacavir use: findings of an FDA meta-analysis [abstract 808]. In: 18th Conference on Retroviruses and Opportunistic Infections Program and Abstracts 2011 27 Feb-2 Mar. 2011; Boston, MA: CROI, 2011.
28. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database (RAMQ). J Acquir Immune Defic Syndr 2011;57:245-53.
29. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009;49:1591-601.
30. Obel N, Farkas DK, Kronborg G, et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010;11:130-6.
31. Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011;52:929-40.
32. SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-24.
33. Forum for Collaborative HIV Research. Review of cardiovascular disease in HIV treatment: from research to the clinic. In: Review of Cardiovascular Disease Risk in Persons Living With HIV. Vienna, Austria, 2010. Available at: http://www.hivforum.org/storage/hivforum/documents/ViennaSatSymp/ vienna%20-%20final, %2018%20july.pdf. Accessed 4 November 2011.
34. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60. (Pubitemid 30660034)
35. van der Laan M, Rose S. Targeted learning: causal inference for observational and experimental data-Springer series in statistics. New York, NY: Springer, 2011.
36. Hernan M, Robins JM. Causal inference. Boca Raton, FL: CRC Press, 2012.
37. Knol MJ, Janssen KJ, Donders AR, et al. Unpredictable bias when using the missing indicator method or complete case analysis for missing confounder values: an empirical example. J Clin Epidemiol 2010;63:728-36.
38. White IR, Carlin JB. Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values. Stat Med 2010;29:2920-31.
39. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96. (Pubitemid 44837777)
40. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
41. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-9. (Pubitemid 27028925)
42. Laine C, Horton R, DeAngelis CD, et al. Clinical trial registration-looking back and moving ahead. N Engl J Med 2007;356:2734-6. (Pubitemid 47001046)
43. 42 U. S. C. § 282 (j), esp. (3) (A) (ii) (I).